Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HKSE:02159's Return-on-Tangible-Asset is ranked better than 91.7% of 687
companies
in the Healthcare Providers & Services industry
Industry Median: 2.59
vs HKSE:02159: 16.72
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Mediwelcome Healthcare Management & Technology Return-on-Tangible-Asset Related Terms
Mediwelcome Healthcare Management & Technology Return-on-Tangible-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02159 vs VEEV, BTSG, TEM: Return-on-Tangible-Asset Comparison
For the Health Information Services subindustry, Mediwelcome Healthcare Management & Technology's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mediwelcome Healthcare Management & Technology Return-on-Tangible-Asset vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Mediwelcome Healthcare Management & Technology's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Mediwelcome Healthcare Management & Technology's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Jun. 2026) net income data.
What does a Return-on-Tangible-Asset of 18.36% mean?
Mediwelcome Healthcare Management & Technology (HKSE:02159) has a Return-on-Tangible-Asset of 18.36% as of Jun. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Mediwelcome Healthcare Management & Technology and its competitors. This is 239% above median its historical median of 5.42. According to the industry distribution chart, Mediwelcome Healthcare Management & Technology ranks #57 out of 687 companies in the Healthcare Providers & Services industry, placing it in the top 8.3%.
Is Mediwelcome Healthcare Management & Technology's Return-on-Tangible-Asset too high?
Mediwelcome Healthcare Management & Technology's current Return-on-Tangible-Asset of 18.36% is 239% above median its 10-year median of 5.42. The Healthcare Providers & Services industry median Return-on-Tangible-Asset is 2.59. Mediwelcome Healthcare Management & Technology's value of 18.36% is 608.9% above this industry median. Based on the distribution chart, Mediwelcome Healthcare Management & Technology ranks #57 out of 687 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Mediwelcome Healthcare Management & Technology has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Mediwelcome Healthcare Management & Technology's Return-on-Tangible-Asset compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Mediwelcome Healthcare Management & Technology ranks #57 out of 687 companies for Return-on-Tangible-Asset. This places Mediwelcome Healthcare Management & Technology in the top 8% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 2.59. Mediwelcome Healthcare Management & Technology's value of 18.36% is 608.9% above this benchmark. While the company's 10-year median is 5.42 vs. the industry median of 2.59, Mediwelcome Healthcare Management & Technology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Healthcare Providers & Services company?
The median Return-on-Tangible-Asset among Healthcare Providers & Services companies is 2.59, based on 687 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mediwelcome Healthcare Management & Technology's current Return-on-Tangible-Asset of 18.36% is 608.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Mediwelcome Healthcare Management & Technology and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Asset is 2.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mediwelcome Healthcare Management & Technology's current Return-on-Tangible-Asset is 18.36%, which is 239% above median its own 10-year median of 5.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mediwelcome Healthcare Management & Technology stock overvalued right now?
Based on GuruFocus' analysis, Mediwelcome Healthcare Management & Technology (HKSE:02159) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.78, compared to a current price of HK$1.68 — trading 115.4% above its estimated fair value. The current Return-on-Tangible-Asset is 18.36%, which is 239% above median its 10-year median of 5.42 and 608.9% above the Healthcare Providers & Services industry median of 2.59. Mediwelcome Healthcare Management & Technology's overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Mediwelcome Healthcare Management & Technology (HKSE:02159), the current Return-on-Tangible-Asset is 18.36% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mediwelcome Healthcare Management & Technology (HKSE:02159) Overvalued in 2026?
Based on GuruFocus' analysis, Mediwelcome Healthcare Management & Technology stock appears to be overvalued.
The current stock price of HK$1.68 is trading 115.4% above its estimated GF Value™ of HK$0.78.
GuruFocus considers Mediwelcome Healthcare Management & Technology to be Significantly Overvalued.
Key valuation signals for HKSE:02159:
Return-on-Tangible-Asset: 18.36% (239% above median its 10-year median of 5.42)
GF Value™: HK$0.78 vs. price of HK$1.68 (115.4% above fair value)
Industry Position: 608.9% above the Healthcare Providers & Services median (#57 of 687)
No single metric tells the full story. See the HKSE:02159 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mediwelcome Healthcare Management & Technology Inc is an investment holding company. The Group mainly provides medical conference services, patient education and screening services, and marketing and consulting services, in addition to providing integrated healthcare marketing solutions. Its products and services include Academic Conference Management System, Scientific Research Data Reporting System, the Health/Medical Media Matrix, patient management services, and marketing and consulting services. The Group has only one reportable segment, mainly operating its businesses in the PRC and earning revenue from the PRC.
54GF Score
Get the complete analysis for HKSE:02159
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02159 has been successfully added to your 
